Allakos (ALLK)
(Delayed Data from NSDQ)
$0.86 USD
-0.02 (-2.44%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $0.87 +0.01 (1.13%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ALLK 0.86 -0.02(-2.44%)
Will ALLK be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ALLK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALLK
Allakos (ALLK): Strong Industry, Solid Earnings Estimate Revisions
Biotech Stock Roundup: VRTX/CRSP Gene Therapy Label Expansion, ALLK Falls on Update
ALLK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Allakos Inc. (ALLK) is Poised for a Turnaround After Losing -61.36% in 4 Weeks
Allakos (ALLK) Plummets 60% on Ending Development of Lead Drug
Is Allakos (ALLK) Stock Outpacing Its Medical Peers This Year?
Other News for ALLK
Allakos’s AK006: A Cautious Hold Amid Anticipation and Uncertainty
Allakos (ALLK) Receives a Hold from TD Cowen
Allakos’s AK006: Favorable Safety Profile but Uncertainties Prompt Hold Rating
Allakos drops after early-stage results for lead asset
Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile